Centre for Pain IMPACT, Neuroscience Research Australia, Sydney, Australia.
School of Health Sciences, Faculty of Medicine, University of New South Wales, Sydney, Australia.
Cochrane Database Syst Rev. 2023 Jun 12;6(6):CD009416. doi: 10.1002/14651858.CD009416.pub3.
Complex regional pain syndrome (CRPS) is a chronic pain condition that usually occurs in a limb following trauma or surgery. It is characterised by persisting pain that is disproportionate in magnitude or duration to the typical course of pain after similar injury. There is currently no consensus regarding the optimal management of CRPS, although a broad range of interventions have been described and are commonly used. This is the first update of the original Cochrane review published in Issue 4, 2013.
To summarise the evidence from Cochrane and non-Cochrane systematic reviews of the efficacy, effectiveness, and safety of any intervention used to reduce pain, disability, or both, in adults with CRPS.
We identified Cochrane reviews and non-Cochrane reviews through a systematic search of Ovid MEDLINE, Ovid Embase, Cochrane Database of Systematic Reviews, CINAHL, PEDro, LILACS and Epistemonikos from inception to October 2022, with no language restrictions. We included systematic reviews of randomised controlled trials that included adults (≥18 years) diagnosed with CRPS, using any diagnostic criteria. Two overview authors independently assessed eligibility, extracted data, and assessed the quality of the reviews and certainty of the evidence using the AMSTAR 2 and GRADE tools respectively. We extracted data for the primary outcomes pain, disability and adverse events, and the secondary outcomes quality of life, emotional well-being, and participants' ratings of satisfaction or improvement with treatment. MAIN RESULTS: We included six Cochrane and 13 non-Cochrane systematic reviews in the previous version of this overview and five Cochrane and 12 non-Cochrane reviews in the current version. Using the AMSTAR 2 tool, we judged Cochrane reviews to have higher methodological quality than non-Cochrane reviews. The studies in the included reviews were typically small and mostly at high risk of bias or of low methodological quality. We found no high-certainty evidence for any comparison. There was low-certainty evidence that bisphosphonates may reduce pain intensity post-intervention (standardised mean difference (SMD) -2.6, 95% confidence interval (CI) -1.8 to -3.4, P = 0.001; I = 81%; 4 trials, n = 181) and moderate-certainty evidence that they are probably associated with increased adverse events of any nature (risk ratio (RR) 2.10, 95% CI 1.27 to 3.47; number needed to treat for an additional harmful outcome (NNTH) 4.6, 95% CI 2.4 to 168.0; 4 trials, n = 181). There was moderate-certainty evidence that lidocaine local anaesthetic sympathetic blockade probably does not reduce pain intensity compared with placebo, and low-certainty evidence that it may not reduce pain intensity compared with ultrasound of the stellate ganglion. No effect size was reported for either comparison. There was low-certainty evidence that topical dimethyl sulfoxide may not reduce pain intensity compared with oral N-acetylcysteine, but no effect size was reported. There was low-certainty evidence that continuous bupivacaine brachial plexus block may reduce pain intensity compared with continuous bupivacaine stellate ganglion block, but no effect size was reported. For a wide range of other commonly used interventions, the certainty in the evidence was very low and provides insufficient evidence to either support or refute their use. Comparisons with low- and very low-certainty evidence should be treated with substantial caution. We did not identify any RCT evidence for routinely used pharmacological interventions for CRPS such as tricyclic antidepressants or opioids.
AUTHORS' CONCLUSIONS: Despite a considerable increase in included evidence compared with the previous version of this overview, we identified no high-certainty evidence for the effectiveness of any therapy for CRPS. Until larger, high-quality trials are undertaken, formulating an evidence-based approach to managing CRPS will remain difficult. Current non-Cochrane systematic reviews of interventions for CRPS are of low methodological quality and should not be relied upon to provide an accurate and comprehensive summary of the evidence.
复杂性区域疼痛综合征 (CRPS) 是一种常见于创伤或手术后肢体的慢性疼痛疾病。其特征是疼痛持续存在,其程度或持续时间与类似损伤后的典型疼痛过程不成比例。目前,对于 CRPS 的最佳治疗方法尚无共识,尽管已经描述了广泛的干预措施并且通常被使用。这是最初发表于 2013 年第 4 期的原始 Cochrane 综述的首次更新。
总结 Cochrane 及非 Cochrane 系统评价中关于任何干预措施在减轻成人 CRPS 疼痛、残疾或两者兼具方面的疗效、有效性和安全性的证据。
我们通过对 Ovid MEDLINE、Ovid Embase、Cochrane 系统评价数据库、CINAHL、PEDro、LILACS 和 Epistemonikos 的系统搜索,识别 Cochrane 评价和非 Cochrane 评价,搜索时间从建库到 2022 年 10 月,无语言限制。我们纳入了包括使用任何诊断标准诊断为 CRPS 的成年人(≥18 岁)的随机对照试验的系统评价。两名综述作者独立评估纳入标准、提取数据,并分别使用 AMSTAR 2 和 GRADE 工具评估评价和证据的质量。我们提取了主要结局(疼痛、残疾和不良事件)和次要结局(生活质量、情绪健康和参与者对治疗满意度或改善的评价)的数据。
我们在之前的综述版本中纳入了 6 项 Cochrane 评价和 13 项非 Cochrane 系统评价,在当前版本中纳入了 5 项 Cochrane 评价和 12 项非 Cochrane 系统评价。使用 AMSTAR 2 工具,我们判断 Cochrane 评价的方法学质量高于非 Cochrane 评价。纳入研究的研究通常规模较小,且大多存在高度偏倚或方法学质量较低的风险。我们没有发现任何比较的高确定性证据。有低确定性证据表明双膦酸盐可能会降低干预后的疼痛强度(标准化均数差(SMD)-2.6,95%置信区间(CI)-1.8 至-3.4,P = 0.001;I = 81%;4 项试验,n = 181),并有中度确定性证据表明它们可能与增加任何性质的不良事件有关(风险比(RR)2.10,95%CI 1.27 至 3.47;需要治疗的额外有害结果数(NNTH)4.6,95%CI 2.4 至 168.0;4 项试验,n = 181)。有中度确定性证据表明利多卡因局部麻醉交感神经阻滞与安慰剂相比可能不会降低疼痛强度,并且有低确定性证据表明与星状神经节的超声相比可能不会降低疼痛强度。对于这两种比较,均未报告效应量。有低确定性证据表明与口服 N-乙酰半胱氨酸相比,局部二甲亚砜可能不会降低疼痛强度,但未报告效应量。有低确定性证据表明连续臂丛阻滞与连续星状神经节阻滞相比可能会降低疼痛强度,但未报告效应量。对于广泛使用的其他常见干预措施,证据的确定性非常低,无法提供支持或反驳其使用的充分证据。对于低确定性和非常低确定性证据的比较应谨慎处理。我们没有发现任何 RCT 证据表明三环类抗抑郁药或阿片类药物等常规用于 CRPS 的药物干预措施有效。
尽管与之前的综述版本相比,纳入的证据有了相当大的增加,但我们没有发现任何疗法对 CRPS 有效性的高确定性证据。在进行更大规模、高质量的试验之前,制定管理 CRPS 的循证方法仍将很困难。目前对 CRPS 干预措施的非 Cochrane 系统评价方法学质量较低,不应依赖这些评价来提供对证据的准确和全面总结。